Literature DB >> 27872067

In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens.

Gregory G Stone1, Patricia A Bradford2, Paul Newell3, Angela Wardman3.   

Abstract

The in vitro activity of ceftazidime-avibactam was evaluated against 341 Gram-negative isolates from 333 patients in a randomized, phase 3 clinical trial of patients with complicated urinary tract or intra-abdominal infections caused by ceftazidime-nonsusceptible pathogens (NCT01644643). Ceftazidime-avibactam MIC90 values against Enterobacteriaceae and Pseudomonas aeruginosa (including several class B or D enzyme producers that avibactam does not inhibit) were 1 and 64 μg/ml, respectively. Overall, the ceftazidime-avibactam activity against ceftazidime-nonsusceptible isolates was comparable to the activity of ceftazidime-avibactam previously reported against ceftazidime-susceptible isolates. (This study has been registered at ClinicalTrials.gov under identifier NCT01644643.).
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  ceftazidime nonsusceptible; ceftazidime-avibactam; in vitro activity

Mesh：

Substances：

Year:  2017        PMID： 27872067      PMCID： PMC5278708          DOI： 10.1128/AAC.01820-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value.

Authors:  Robert K Flamm; Gregory G Stone; Helio S Sader; Ronald N Jones; Wright W Nichols
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

2.  Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.

Authors:  Yehuda Carmeli; Jon Armstrong; Peter J Laud; Paul Newell; Greg Stone; Angela Wardman; Leanne B Gasink
Journal:  Lancet Infect Dis       Date:  2016-04-20       Impact factor: 25.071

3.  Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.

Authors:  Helio S Sader; Mariana Castanheira; Rodrigo E Mendes; Robert K Flamm; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

4.  In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates.

Authors:  Premavathy Levasseur; Anne-Marie Girard; Monique Claudon; Herman Goossens; Michael T Black; Kenneth Coleman; Christine Miossec
Journal:  Antimicrob Agents Chemother       Date:  2012-01-03       Impact factor: 5.191

5.  In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.

Authors:  Henry Li; Mark Estabrook; George A Jacoby; Wright W Nichols; Raymond T Testa; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

6.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

Review 7.  Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.

Authors:  George G Zhanel; Christopher D Lawson; Heather Adam; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Andrew Denisuik; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

8.  In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.

Authors:  Thérèse Stachyra; Premavathy Levasseur; Marie-Claude Péchereau; Anne-Marie Girard; Monique Claudon; Christine Miossec; Michael T Black
Journal:  J Antimicrob Chemother       Date:  2009-06-02       Impact factor: 5.790
  8 in total
  10 in total

1.  In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial.

Authors:  Gregory G Stone; Patricia A Bradford; Margaret Tawadrous; Dianna Taylor; Mary Jane Cadatal; Zhangjing Chen; Joseph W Chow
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

2.  In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Authors:  James A Karlowsky; Krystyna M Kazmierczak; Samuel K Bouchillon; Boudewijn L M de Jonge; Gregory G Stone; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

3.  In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections.

Authors:  Gregory G Stone; Paul Newell; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

Review 4.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

5.  Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points.

Authors:  Antoni Torres; Doug Rank; David Melnick; Ludmyla Rekeda; Xiang Chen; Todd Riccobene; Ian A Critchley; Hassan D Lakkis; Dianna Taylor; Angela K Talley
Journal:  Open Forum Infect Dis       Date:  2019-04-25       Impact factor: 3.835

6.  In vitro activity of ceftazidime-avibactam against Gram-negative strains in patients with complicated urinary tract infection and complicated intra-abdominal infection in Colombia 2014-2018.

Authors:  Elkin V Lemos-Luengas; Sixta Rentería-Valoyes; Paola Cárdenas-Isaza; Jorge A Ramos-Castaneda
Journal:  Braz J Infect Dis       Date:  2022-05-23       Impact factor: 3.257

7.  The Dynamics of Antimicrobial Resistance among Enterobacteriaceae Isolates in Russia: Results of the 2012-2018 INFORM and ATLAS International Program Studies.

Authors:  Roman Kozlov; Alexey Kuzmenkov
Journal:  Antibiotics (Basel)       Date:  2022-06-10

8.  In Vitro Activity of Newer and Conventional Antimicrobial Agents, Including Fosfomycin and Colistin, against Selected Gram-Negative Bacilli in Kuwait.

Authors:  Wadha Alfouzan; Rita Dhar; David P Nicolau
Journal:  Pathogens       Date:  2018-09-17

Review 9.  The Efficacy of Using Combination Therapy against Multi-Drug and Extensively Drug-Resistant Pseudomonas aeruginosa in Clinical Settings.

Authors:  Frank Jones; Yanmin Hu; Anthony Coates
Journal:  Antibiotics (Basel)       Date:  2022-02-28

10.  Epidemiology of resistance of carbapenemase-producing Klebsiella pneumoniae to ceftazidime-avibactam in a Chinese hospital.

Authors:  D Chen; L Xiao; D Hong; Y Zhao; X Hu; S Shi; F Chen
Journal:  J Appl Microbiol       Date:  2021-07-22       Impact factor: 4.059
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.